Clarified Precision Medicine operates a scalable asynchronous Molecular Tumor Board that interprets genomic tumor profiling using NCCN guidelines, enabling oncologists to make informed treatment decisions based on individual tumor profiles. The platform enhances the utilization of targeted therapies, resulting in a 50% increase in appropriate clinical recommendations and reducing the time spent on data interpretation by up to one hour per patient.
Funding
Funding not disclosed
Founders
Product
Problem
Oncologists face challenges in keeping up with the rapidly evolving landscape of cancer research, including new targetable mutations and advances in targeted treatments. The complexity of genomic data makes it difficult to accurately interpret results and apply them to treatment decisions, while limited access to molecular tumor boards can cause delays in treatment planning.
Solution
Clarified Precision Medicine offers a scalable, asynchronous Molecular Tumor Board that interprets genomic tumor profiling based on NCCN guidelines, providing oncologists with actionable insights for precision therapy. The platform leverages a medical practice supported by a technology platform and AI to deliver expert-reviewed treatment options tailored to individual tumor profiles (somatic, germline, or liquid). By integrating seamlessly into clinical workflows, Clarified Precision Medicine helps physicians identify the most effective targeted therapies, leading to faster and more confident treatment decisions. The platform also enhances the utilization of guidelines-based next-generation sequencing (NGS) tests.
Target Audience
The primary target audience includes oncologists, hospitals, and healthcare systems seeking to enhance their precision oncology programs, as well as pharmaceutical companies and labs looking to optimize the identification of actionable mutations and improve the utilization of targeted therapies.
Features
- Expert-reviewed treatment options based on individual tumor profiles (somatic, germline, or liquid)
- Integration of somatic, germline, and liquid biopsy results
- AI-driven analysis of genomic data, combined with expert medical review
- Pharmacogenomics guidance on gene-to-drug interactions for risk management, including pain, depression, anxiety, and toxicity
- Identification of appropriate NGS panels based on patient history
- Programmatic support to develop and sustain in-house Precision Medicine Tumor Boards
- Data analysis to enhance the value and marketability of existing clinical resources